Arecor and Sequel Med Tech to host fireside panel

Summary by AI BETAClose X

Arecor Therapeutics plc and Sequel Med Tech LLC are co-hosting a virtual panel discussion on January 7th, featuring key opinion leaders in diabetes care to discuss innovation in the insulin pump market and the treatment journey for individuals with diabetes. The discussion will highlight Arecor's AT278 ultra-concentrated, ultra-rapid insulin and Sequel's twiist device, focusing on their co-development and the future of automated insulin delivery systems. This event aims to explore advancements that can reduce the daily management burden and improve outcomes for people with diabetes on intensive insulin therapy.

Disclaimer*

UK 100

Latest directors dealings